Akebia Therapeutics Inc. buy Piper Sandler
Start price
31.05.23
/
50%
€0.92
Target price
31.05.24
-
Performance (%)
13.76%
End price
01.06.24
€1.05
Summary
This prediction ended on 01.06.24 with a price of €1.05. The prediction had a final performance of 13.76%. Piper_Sandler has a follow-up prediction for Akebia Therapeutics Inc. where he still thinks Akebia Therapeutics Inc. is a Buy. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Akebia Therapeutics Inc. | 7.453% | 7.453% | -20.505% |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% |
Comments by Piper_Sandler for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating.
Ratings data for AKBA provided by MarketBeat
In the thread Trading Akebia Therapeutics Inc.
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten
Current prediction by Piper_Sandler for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.97
14.03.25
14.03.25
€5.53
14.03.26
14.03.26
-30.31%
15.12.25
15.12.25
